Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00504673
NCT00504673
Completed
Phase 3

Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes

Novo Nordisk A/S0 sites277 target enrollmentApril 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetesDiabetes Mellitus, Type 2
Drugsinsulin detemirinsulin NPHinsulin aspart

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Diabetes
Sponsor
Novo Nordisk A/S
Enrollment
277
Primary Endpoint
Body weight loss
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.

Registry
clinicaltrials.gov
Start Date
April 2005
End Date
December 2006
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •HbA1c: 7.5-11.0%
  • •BMI: 25-40 kg/m2

Exclusion Criteria

  • •Treatment with any OAD (Oral Antidiabetic Drugs) except metformin

Outcomes

Primary Outcomes

Body weight loss

Time Frame: after 26 weeks of treatment

Secondary Outcomes

  • HbA1c
  • Incidence of hypoglycaemia

Similar Trials

Completed
Phase 3
Efficacy and Safety of Insulin Detemir in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1
NCT00595374Novo Nordisk A/S114
Terminated
Phase 4
Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT00506662Novo Nordisk A/S86
Completed
Phase 3
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT00856986Novo Nordisk A/S987
Completed
Phase 3
Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1
NCT00184639Novo Nordisk A/S71
Completed
Phase 3
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT00104182Novo Nordisk A/S503